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IL-17 plays a central role in several types of 
autoimmune inflammation and provides resis-
tance to certain infections (Weaver et al., 2006; 
Reiner, 2007; Rudner et al., 2007; Zelante et al., 
2007). Mice that lack IL-17 or IL-17 receptor 
are resistant to multiple autoimmune condi-
tions and are susceptible to certain infections. 
In humans, IL-17 levels in the serum correlate 
well with the severity of several autoimmune 
and inflammatory conditions, suggesting that 
IL-17 is a promising target for these diseases 
(Iwakura and Ishigame, 2006; Burlingham et al., 
2007). A major source of IL-17 is a distinct subset 
of Th cells termed Th17 cells. These cells pro-
duce abundant amounts of IL-17, IL-21, IL-22, 
and IL-6 (Weaver et al., 2006; Reiner, 2007; 
Zhou et al., 2007).
Differentiation of Th17 cells is guided by 
retinoic acid receptor–related orphan nuclear re-
ceptors (RORs)  and t (Ivanov et al., 2007; 
Yang et al., 2008b), which are activated by vari-
ous stimuli such as IL-1, TGF-, and IL-6 
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Interleukin (IL)-17–producing T helper (Th17) cells play a critical role in the pathophysi-
ology of several autoimmune disorders. The differentiation of Th17 cells requires the 
simultaneous presence of an unusual combination of cytokines: IL-6, a proinflammatory 
cytokine, and transforming growth factor (TGF) , an antiinflammatory cytokine. How-
ever, the molecular mechanisms by which TGF- exerts its effects on Th17 cell differen-
tiation remain elusive. We report that TGF- does not directly promote Th17 cell 
differentiation but instead acts indirectly by blocking expression of the transcription 
factors signal transducer and activator of transcription (STAT) 4 and GATA-3, thus pre-
venting Th1 and Th2 cell differentiation. In contrast, TGF- had no effect on the expres-
sion of retinoic acid receptor–related orphan nuclear receptor t, a Th17-specific 
transcription factor. Interestingly, in Stat-6/T-bet/ mice, which are unable to gener-
ate Th1 and Th2 cells, IL-6 alone was sufficient to induce robust differentiation of Th17 
cells, whereas TGF- had no effect, suggesting that TGF- is dispensable for Th17 cell 
development. Consequently, BALB/c Stat-6/T-bet/ mice, but not wild-type BALB/c 
mice, were highly susceptible to the development of experimental autoimmune encepha-
lomyelitis, which could be blocked by anti–IL-17 antibodies but not by anti–TGF- 
antibodies. Collectively, these data provide evidence that TGF- is not directly required 
for the molecular orchestration of Th17 cell differentiation.
© 2009 Das et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS
IL-6 is sufficient to drive Th17 cell differentiation  
in Stat-6/T-bet/ mice
It has been previously shown that activation of the Th1 and 
Th2 lineage-specific transcription factors T-bet and GATA-3, 
respectively, or simply addition of cytokines that are pro-
duced by Th1 and Th2 cells drastically inhibits Th17 cell 
differentiation (Harrington et al., 2005; Mathur et al., 2006). 
Therefore, to study the differentiation of Th17 cells in the 
absence of Th1 and Th2 cells, we generated Stat-6/T-
bet/ double knockout mice. CD4+CD25CD62LhiCD44lo 
naive T cells were sorted to a purity level of ≥99.5% from 
wild-type, Stat-6/, T-bet/, and Stat-6/T-bet/ mice 
(Fig. S1 A). We found that upon activation, cells from Stat-
6/T-bet/ mice were unable to produce signature cyto-
kines associated with both the Th1 and Th2 cell phenotypes. 
As  expected,  cells  from  T-bet/  mice  failed  to  produce 
IFN-, whereas cells from Stat-6/ mice failed to produce 
IL-4 (Fig. S1 B). To determine the role of IL-6 and/or TGF- 
in the differentiation of Th17 cells, we activated FACS-
sorted naive CD4+ T cells derived from each of these mouse 
strains  with  anti-CD3  and  anti-CD28  in  the  presence  of 
TGF-, IL-6, or both. We found that IL-6 was sufficient to 
induce a robust Th17 cell differentiation in naive CD4+ T 
cells isolated from Stat-6/T-bet/ mice. Addition of 
TGF- had no significant effect on the differentiation of 
Th17 cells (Fig. 1 A). In contrast, differentiation of Th17 cells 
from wild-type, Stat-6/, and T-bet/ mice required the 
presence of both IL-6 and TGF- (Fig. 1 A). By measuring 
the expression of IL-21 and IL-17 in the resultant cells, we 
found that IL-6 was sufficient to induce expression of IL-17 
in Stat-6/T-bet/ CD4+ T cells but not in wild-type cells 
(Fig. 1 B). Therefore, these results strongly suggest that TGF- 
does not act directly in promoting the differentiation of 
Th17 cells but rather provides an environment that is condu-
cive to the differentiation of Th17 cells, likely by inhibiting 
the differentiation of Th1 and Th2 cells. To test whether the 
production of TGF- plays a role in the differentiation of 
Th17 cells in Stat-6/T-bet/ mice, we performed similar 
experiments with anti–TGF- antibodies. Addition of anti–
TGF- had no effect on IL-6–mediated differentiation of 
Th17 cells in Stat-6/T-bet/ mice (Fig. 1 A). However, 
IL-6 alone was not sufficient to induce Th17 cell differentia-
tion from naive CD4+ T cells derived from wild-type mice, 
but neutralization of TGF- with anti–TGF- antibodies at 
a concentration of 10 µg/ml completely abrogated Th17 cell 
differentiation (Fig. S2 A).
To determine whether inhibition of Th1 cells or Th2 cells 
alone is sufficient to generate a robust Th17 cell response, we 
examined Th17 cell differentiation in CD4+ cells isolated from 
T-bet/ and Stat-6/ mice. We found that neither of these 
mouse strains was able to mount Th17 cell responses to levels 
comparable with Stat-6/T-bet/ mice (Fig. 1, A and B), 
suggesting that simultaneous inhibition of Th1 and Th2 cell 
differentiation is critical for optimal Th17 cell development in 
the absence of TGF-.
(Bettelli et al., 2006; Mangan et al., 2006). Additionally, IL-6– 
and IL-21–induced activation of transcription factor STAT-3 
also plays a key role in Th17 cell differentiation (Yang et al., 
2007). Thus, mice deficient in RORt or STAT-3 are unable 
to generate Th17 cells (Zhou et al., 2007). On the other hand, 
IL-2–induced activation of STAT-5 dramatically inhibits Th17 
cell differentiation (Laurence et al., 2007). Th17 cells do not 
express the Th1- and Th2-specific transcription factors T-bet 
and GATA-3. Interestingly, activation of these Th subset lineage-
specific transcription factors hinders the differentiation of 
Th17 cells (Harrington et al., 2005; Mathur et al., 2006; Tato 
et al., 2006; Veldhoen et al., 2006).
The roles of several cytokines in Th17 cell differentia-
tion have been studied. Initially, it was thought that IL-23 
played a critical role in Th17 cell differentiation (Langrish   
et al., 2005; Kikly et al., 2006). However, recent studies have 
indicated that IL-23 is involved in promoting the effector 
functions of Th17 cells (Khader et al., 2007). IL-21, a cyto-
kine of the IL-2 family, was found to profoundly promote 
Th17 cell expansion and assist the differentiation of Th17 
cells (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 
2007), whereas IL-2 drastically inhibited Th17 cell differen-
tiation (Laurence et al., 2007; Stockinger, 2007). Similarly, 
many other cytokines, including IL-4, IL-12, IL-27, and type 
I and II IFNs, have also been shown to inhibit Th17 cell 
differentiation (Harrington et al., 2005; Park et al., 2005; 
Weaver et al., 2007; Guo et al., 2008).
Recent studies have demonstrated that the differentiation 
of Th17 cells in vitro requires an unusual but key combina-
tion of two cytokines: IL-6, a proinflammatory cytokine, and 
TGF-, an antiinflammatory cytokine (Bettelli et al., 2006; 
Mangan et al., 2006; Veldhoen et al., 2006). Although TGF- 
enhances Th17 cell differentiation, it also inhibits Th1 and 
Th2 cell differentiation (Li et al., 2007). Additionally, both 
Th1 and Th2 cytokines have been shown to potently inhibit 
the development of Th17 cells (Park et al., 2005). To deter-
mine the mechanism by which TGF- promotes Th17 dif-
ferentiation, we investigated whether TGF- acts directly on 
the molecular orchestration of Th17 cell differentiation or 
indirectly through its inhibition of the differentiation of Th1 
and Th2 cells. In this paper, we show that mice that are   
incapable  of  mounting  both  Th1  and  Th2  cell  responses 
(Stat-6/T-bet/ mice) develop robust experimental auto-
immune encephalomyelitis (EAE), even in a genetic back-
ground (BALB/c) that is normally resistant to the development 
of EAE. The CD4+ T cells isolated from these mice gener-
ated vigorous Th17 cell responses in IL-6–supplemented cul-
tures regardless of the presence of TGF-. The presence of 
TGF- strongly inhibited STAT-4 and GATA-3 expression 
in differentiating and committed Th1 and Th2 cells derived 
from wild-type mice, whereas RORt expression remained 
unaffected in either condition. Collectively, these data indi-
cate that TGF- is dispensable for the molecular orchestra-
tion of Th17 cell differentiation and instead promotes Th17 
cell differentiation by inhibiting the differentiation of Th1 
and Th2 cells.JEM VOL. 206, October 26, 2009 
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anti-CD28, these cells also exhibited dramatic Th17 cell dif-
ferentiation in the absence of TGF- signaling (Fig. 2 A). 
To further test whether this phenomenon is only limited to 
gene knockout and chimeric animals, we performed experi-
ments with naive CD4+ T cells from wild-type BALB/c and 
To verify the role of TGF- in the differentiation of 
Th17  cells,  we  bred  Stat-6/T-bet/  mice  with  mice 
transgenic for a dominant-negative TGF-RII (TGF-RI-
IDN) and isolated CD4+ T cells from these Stat-6/T-bet//
TGF-RIIDN mice. Upon activation with anti-CD3 and 
Figure 1.  Differentiation of Th17 cells in the absence of Th1, Th2, or Th1 and Th2 cells. (A) FACS-sorted CD25CD62LhiCD44lo naive CD4+ T cells 
isolated from wild-type, Stat-6/, T-bet/, or Stat-6/T-bet/ mice were activated by plate-bound anti-CD3 and anti-CD28 in the presence of 5 ng/ml 
TGF-, 20 ng/ml IL-6, or both for 72 h. Intracellular cytokines were detected as described in Materials and methods. The percentage of cells positive for 
IL-17 is shown from one representative out of three independent experiments. (B) Expression of IL-17 and IL-21 in cells treated as in A was determined by 
quantitative PCR. (C) Naive CD4+ T cells from Stat-6/T-bet//TGF-RIIDN mice were subjected to Th17 cell differentiation as described in A. Note that 
these mice and their control littermates are in a mixed genetic background. Results shown are representative of three independent experiments. Four 
mice per group were used in each experiment.2410 TGF- IS DISPENSABLE FOR TH17 CELL DIFFERENTIATION | Das et al.
TGF- plays a critical role in the regulation of the differ-
entiation of T reg and Th17 cells (Wahl and Chen, 2003). 
The fine balance between RORt and FoxP3 is critical in 
controlling the differentiation of T reg and Th17 cell re-
sponses (Lochner et al., 2008). Therefore, we evaluated the 
expression of FoxP3 in CD4+ T cells differentiated under 
C57BL/6 mice by blocking Th1 and Th2 cell differentiation 
with a combination of antibodies against IL-4, IFN-, and 
IL-12. We found that under these conditions, IL-6 alone 
was also sufficient to induce robust Th17 cell differentiation, 
whereas the presence of TGF- had no substantial effect 
(Fig. S2 B).
Figure 2.  Regulation of transcription factors in Th cells by TGF- and IL-6. FACS-sorted CD25CD62LhiCD44lo naive CD4+ T cells were activated 
with plate-bound anti-CD3 and anti-CD28 in the presence of 5 ng/ml TGF-, 20 ng/ml IL-6, or both for 48 h. Anti–TGF- was added at a concentra-
tion of 10 µg/ml. Expression levels of the transcription factors RORt, GATA-3, Stat-6, Stat-4, and Tbx21 in the cells were determined by quantitative PCR. 
Results shown are representative of three independent experiments.JEM VOL. 206, October 26, 2009 
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were suppressed by TGF- supplementation, whereas IL-6 
had a marginal effect on IFN- production but had no effect 
on IL-4 production. As shown in Fig. 1, the production of 
IL-17 was enhanced only in the presence of both TGF- and 
IL-6 (Fig. 3 A). To further determine whether the presence 
of Th1 or Th2 cytokines affects the response to TGF- and 
IL-6,  we  examined  the  expression  of  RORt,  GATA-3, 
STAT-4, and T-bet in differentiated Th1, Th2, and Th17 
cells derived from wild-type mice treated with TGF-, IL-6, 
or both. Unlike in naive CD4+ T cells (Fig. 2), IL-6 had no 
effect on the expression of these transcription factors in dif-
ferentiated Th1, Th2, and Th17 cells. On the other hand, 
TGF- alone effectively inhibited GATA-3 and STAT-4 ex-
pression, and to some extent T-bet expression, in these cells 
(Fig. 3 B). Similar to naive T cells, however, STAT-6 expres-
sion was unaffected in differentiating and fully differentiated 
Th1 and Th2 cells (unpublished data). Therefore, we con-
clude that TGF- inhibits GATA-3 and STAT-4 expression 
in both differentiating and fully differentiated Th cells.
Stat-6/T-bet/ mice develop robust EAE
Th17 cells have been implicated in many autoimmune disor-
ders, including EAE (Sutton et al., 2006). As an animal model 
for multiple sclerosis, EAE can be induced only in certain 
mouse strains such as SJL/J, whereas strains such as BALB/c 
are completely resistant. This resistance is not caused by unre-
sponsiveness to neuroantigens, because it has been shown that 
BALB/c mice can generate myelin basic protein (MBP)–
specific pathogenic T cells, which can induce EAE in immuno-
deficient  mice  upon  adoptive  transfer  (Jones  et  al.,  1993; 
Lafaille et al., 1997). Because we found a robust Th17 cell re-
sponse in Stat-6/T-bet/ mice (Fig. 1 A), we next tested 
whether Th1 and Th2 cells inhibit the generation of Th17 cells 
in vivo and if their presence prevents the development of EAE 
in BALB/c mice. We found that Stat-6/T-bet/ mice on 
the BALB/c background were capable of developing MBP-
induced EAE, whereas wild-type BALB/c, Stat-6/, and   
T-bet/ mice developed very mild EAE (Fig. 4 A and Fig. S4). 
To test whether IL-17 is responsible for the pathology of EAE 
in these mice, we performed antibody neutralizations of IL-17 
and TGF-. Interestingly, administration of anti–IL-17 ame-
liorated EAE in Stat-6/T-bet/ mice, whereas treatment 
with anti–TGF- had no effect (Fig. 4 A). However, treatment 
with anti–IL-6 significantly inhibited the development of EAE 
in these animals (Fig. S4), which is in agreement with pub-
lished data (Gijbels et al., 1995). Previous studies have shown 
that IL-6–deficient animals are resistant to EAE (Samoilova   
et al., 1998). Blockade of IL-6 signaling by means of antibodies 
is in clinical trials for treatment of multiple sclerosis and other 
inflammatory diseases (Paul-Pletzer, 2006). We also found that 
MBP-specific proliferation of T cells from Stat-6/T-bet/ 
mice was similar to that of their wild-type littermates (Fig. 4 B), 
suggesting normal T cell priming events. However, the ob-
served EAE in Stat-6/T-bet/ mice could be caused by a 
defect in IL-10–producing cells. Therefore, to test this possi-
bility we analyzed IL-10– and IL-17–producing cells in the 
different conditions. We did not find significant differences 
in FoxP3 expression in CD4+ T cells isolated from any of the 
mouse strains investigated and cultured under Th17 cell dif-
ferentiation conditions (Fig. S3). Therefore, abnormal differ-
entiation of T reg cells is not the cause of robust differentiation 
of Th17 cells in Stat-6/T-bet/ mice.
TGF- inhibits STAT-4 and GATA-3 expression  
in developing Th1 and Th2 cells
The experiments described in the previous section were per-
formed with T cells that developed in the absence of Th1 and 
Th2 cells. To further verify that TGF- exerts its function on 
Th17 cell differentiation by inhibiting Th1 and Th2 cell dif-
ferentiation rather than by acting directly on Th17 cells, we 
treated naive CD4+ T cells from wild-type mice with TGF- 
alone during their initial activation. We found that TGF- 
did not significantly affect the expression of RORt, although 
a dramatic increase in the expression of this orphan receptor 
was  observed  when  both  TGF-  and  IL-6  were  present   
(Fig. 2). Interestingly, treatment with TGF- alone or together 
with IL-6 prevented the expression of STAT-4 and GATA-3 
(Fig. 2). Surprisingly, expression of STAT-6 was unaltered by 
treatment with TGF-, either alone or in combination with 
IL-6. Similarly, a very marginal effect on the expression of   
T-bet was noted (Fig. 2). Therefore, these findings indicate 
that TGF- inhibits Th1 and Th2 cell differentiation specifi-
cally through down-regulation of STAT-4 and GATA-3. It is 
important to emphasize that mice deficient in STAT-4, simi-
lar to those deficient in T-bet, are defective in the generation 
of Th1 cell responses (Kaplan et al., 1996).
Although GATA-3 knockout mice are embryonically 
lethal, it has been shown that the lack of Th2 cytokine pro-
duction in mice deficient in the p50 subunit of NF-B is 
caused by the inability of T cells from these animals to ex-
press GATA-3 (Das et al., 2001). Therefore, to further ver-
ify that the effect of TGF- on Th17 cell differentiation is 
exerted through the regulation of STAT-4 and GATA-3 
expression, we examined the effect of IL-6 and TGF- on 
these transcription factors in CD4+ T cells from Stat-6/ 
and T-bet/ mice. As shown in Fig. 2, CD4+ T cells from 
Stat-6/ mice did not express detectable levels of GATA-3 
but expressed high levels of STAT-4, and the latter became 
suppressed  by  culture  in  the  presence  of  TGF-.  Con-
versely, T-bet/ T cells expressed low levels of STAT-4 
but high levels of GATA-3, and the latter was also inhibited 
by TGF-. Therefore, we conclude that T-bet and STAT-4, 
as well as STAT-6 and GATA-3, coordinately promote the 
differentiation of Th cells.
Regulation of Th1, Th2, and Th17 signature cytokines  
and transcription factors by TGF-
In the preceding experiments, we have shown that TGF- 
inhibits the expression of STAT-4 and GATA-3 in develop-
ing T cells. Next, we examined the effect of TGF-, alone or 
together with IL-6, on the cytokine expression profile of 
CD4+ T cells. We found that both Th1 and Th2 cytokines 2412 TGF- IS DISPENSABLE FOR TH17 CELL DIFFERENTIATION | Das et al.
achieved experimentally with antibodies directed against 
these opposing cytokines (anti–IL-4 during the differentia-
tion of Th1 cells and anti–IL-12 for Th2 cell differentiation). 
In contrast, current evidence indicates that Th17 cell differ-
entiation is dependent on two cytokines: IL-6 and TGF-. 
The physiological functions of these two cytokines are con-
trasting, and most notably, TGF- inhibits many immuno-
logical functions, including the production and function of 
IL-6 (Musso et al., 1990). Thus, we examined how these two 
cytokines unite for a common purpose in the differentiation 
of Th17 cells. Our data demonstrate that TGF- is dispens-
able for the molecular orchestration of Th17 cell differentia-
tion. Rather, TGF- potently inhibits Th1 and Th2 cell 
differentiation by preventing expression of STAT-4 and 
GATA-3. Strikingly, our in vitro studies revealed that IL-6 is 
responsible for the differentiation of Th17 cells only when 
Th1  and  Th2  cell  differentiation  mechanisms  are  absent, 
which can be achieved by including TGF- in the culture 
medium. Furthermore, similar results were obtained when 
lymph nodes of animals that were immunized with MBP. 
Intracellular cytokine staining showed a dramatic enhance-
ment of IL-17–producing CD4+ T cells, but there was no 
significant  difference  in  IL-10–producing  cells  between 
Stat-6/T-bet/  mice  and  their  wild-type  littermates 
(Fig. 4 C). Collectively, these results provide further evidence 
that TGF- does not act directly on Th17 cells in promoting 
their differentiation in vivo.
DISCUSSION
Th17 cells are the newest addition to the growing family of 
Th cell subsets, and are distinct from Th1 and Th2 cells in 
their cytokine production profile, functions, and differentia-
tion (Harrington et al., 2005). The molecular basis of Th17 
cell function and differentiation is poorly understood. The 
molecular orchestration of Th1 and Th2 cell differentiation 
requires unique key cytokines, i.e., IL-12 and IL-4, respec-
tively. However, optimal differentiation of these cell subsets 
requires  the  absence  of  inhibitory  factors,  which  can  be 
Figure 3.  TGF- inhibits GATA-3 and STAT-4 expression in T cells during activation. (A) Naive CD4+ T cells were activated with plate-bound 
anti-CD3 and anti-CD28 in the presence of 5 ng/ml TGF-, 20 ng/ml IL-6, or both for 48 h. Cytokines in the supernatants were determined by multiplexed 
bead array immunoassay. Data represent means ± SEM. (B) Established Th1 and Th2 cells were activated by plate-bound anti-CD3 for 6 h with or without 
5 ng/ml TGF-, 20 ng/ml IL-6, or both. The expression of transcription factors was determined by quantitative PCR. Data shown are representative of four 
independent experiments. *, P < 0.03; **, P < 0.002; ***, P < 0.001; #, P < 0.003; ##, P < 0.01; and ###, P < 0.005.JEM VOL. 206, October 26, 2009 
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than CD4+ T cells from wild-type animals (Fig. 1). Similarly, 
mice deficient in STAT-6 show increased Th17 cell differen-
tiation compared with wild-type mice (Fig. 1). Even greater 
Th17 polarization was achieved in CD4+ T cells from Stat-6 
and T-bet double-knockout mice. Therefore, we tested 
whether resistance to EAE in BALB/c mice could be attrib-
uted to the presence of Th1 and Th2 cells. Previous studies 
have shown that upon immunization with MBP, BALB/c 
mice produce MBP-specific pathogenic Th cells that can in-
duce EAE upon adoptive transfer (Jones et al., 1993; Lafaille 
et al., 1997). Therefore, resistance to EAE in BALB/c mice 
is not MHC mediated. However, we found that Stat-6/ 
T-bet/ mice, which are deficient in both Th1 and Th2 cells, 
develop strong Th17 cell responses and exhibit robust EAE. 
These results indicate that conditions that drive the develop-
ment of either Th1 or Th2 cells inhibit Th17 cell differentia-
tion, thus mediating the resistance of BALB/c mice to EAE.
Th1 and Th2 cell differentiation mechanisms were abolished 
by genetic ablation of essential transcription factors (Fig. 1). 
This conclusion is further supported by our results that in 
mice  deficient  in  both  Th1  and  Th2  cell  differentiation 
mechanisms, genetic interruption of TGF- receptor signal-
ing failed to affect Th17 cell differentiation. Therefore, Th17 
cell differentiation can be achieved without the presence of 
TGF- as long as Th1 and Th2 cytokines are absent.
The development of EAE is dependent on Th17 cells 
(Ivanov et al., 2007). Previously, it has been shown that mice 
that are deficient in Th1 cell differentiation exhibit a higher 
incidence of EAE, suggesting that Th1 cells play an inhibi-
tory  role  in  EAE  pathogenesis  (Mattner  et  al.,  2000;  Lin   
et al., 2006). Subsequently, it was reported that T-bet up-
regulation antagonizes Th17 cell differentiation (Mathur et al., 
2006). Our results indicate that CD4+ T cells from T-bet–
deficient mice differentiate more effectively into Th17 cells 
Figure 4.  Stat-6/T-bet/ mice develop EAE in an IL-17–dependent manner. (A) Induction of EAE in wild-type and Stat-6/T-bet/ mice on 
the BALB/c background. Stat-6/T-bet/ mice were injected with neutralizing antibodies against TGF- or IL-17 twice weekly, EAE was induced, and 
clinical disease was scored. Data are from five mice per group and are representative of two independent experiments. (B) Antigen-specific proliferation 
of T cells from wild-type and Stat-6/T-bet/ mice. CD4+ T cells were isolated from MBP-immunized mice, mixed with syngeneic spleen cells at a 1:2 
ratio, and challenged with MBP. After 2 d, proliferation was measured by [3H]thymidine incorporation. Data represent means ± SEM. (C) Intracellular 
cytokine staining for IL-10 and IL-17 was performed in lymph node cells isolated from MBP-immunized mice. Cells were stimulated ex vivo with MBP, 
and their intracellular cytokines were detected as described in Materials and methods. For B and C, results shown are representative of three independent 
experiments, and three mice were used per group.2414 TGF- IS DISPENSABLE FOR TH17 CELL DIFFERENTIATION | Das et al.
MATERIALS AND METHODS
Animals, cytokines, and antibodies. BALB/c, STAT-6 knockout (Stat-
6/),  T-bet  knockout  (T-bet/),  and  TGF-RIIDN  transgenic  mice 
were purchased from The Jackson Laboratory. Stat-6/T-bet/ double-
knockout mice were generated by crossbreeding Stat-6/ and T-bet/ 
mice. TGF-RIIDN/Stat-6/T-bet/ mice were generated by crossing 
TGF-RIIDN and Stat-6/T-bet/ mice. Mice of either sex were used 
at 8–16 wk of age. Mice were housed in a specific pathogen-free colony in 
the vivarium of the Robert Wood Johnson Medical School. The animal 
protocols for the experiments described in this paper were approved by the 
Institutional Animal Care and Use Committee of the Robert Wood Johnson 
Medical  School.  Fluorochrome-conjugated  antibodies  against  IFN- 
(XMG1.2) and IL-17 (TC11-18H10), and unconjugated antibodies to CD3 
(145.2C11), CD28 (37.51.1), and CD4 (GK1.5) were purchased from BD. 
Antibodies to cytokines (IL-4, IL-6, IL-12, IFN-, and TGF-) were pur-
chased from R&D Systems. IL-17 (MM17F3)–neutralizing antibodies were 
purchased from eBioscience.
Differentiation of Th cell subsets. Naive CD25CD62LhiCD44lo CD4+ 
T cells were sorted from splenocytes by using a FACSDiva (BD). These cells 
were differentiated under Th1- or Th2-generating conditions. In brief, 106 
CD4+ lymphocytes/ml were activated with 1 µg/ml anti-CD3 bound to 
plastic and 2 µg/ml of soluble anti-CD28. 10 ng/ml IL-12 and 10 µg/ml 
anti–IL-4 were included in Th1 cultures, whereas 5 ng/ml IL-4, anti–IL-12, 
and anti–IFN- (each at 10 µg/ml) were supplied for Th2 cultures. After 24 h, 
IL-2 was added to all cultures. Cells were divided at a 1:4 ratio after 3 d 
and allowed to rest under the described cytokine conditions in the absence 
of anti-CD3 and anti-CD28 for another 2 d. Differentiation of Th17 cells 
was performed as previously described (Bettelli et al., 2006; Mangan et al., 
2006). In brief, FACS-sorted naive CD4+ T cells were activated on plate-
bound anti-CD3 and anti-CD28 in the presence of 5 ng/ml TGF-, 20 ng/ml 
IL-6, or both. Cultures were terminated after different time points for analy-
sis of mRNA expression and cytokines produced in the supernatants. All cell 
cultures were maintained in RPMI 1640 medium supplemented with 2 mM 
l-glutamine, 50 µM 2-mercaptoethanol, 10% heat-inactivated FBS, and   
10 mM gentamycin.
Flow cytometric staining and analysis. For cell-surface staining, cells 
were suspended in staining buffer (PBS, 3% FCS, 0.01% Na-azide) at a con-
centration of 107 cells/ml, and 50 µl of suspension was incubated with fluo-
rescent antibodies for 30 min on ice. Cells were washed twice with staining 
buffer and fixed with 1% paraformaldehyde. For intracellular cytokine stain-
ing, cells were treated with 50 ng/ml PMA and 750 ng/ml ionomycin with 
10 µg/ml brefeldin A (Sigma-Aldrich) added during the last 6 h of culture. 
For the determination of cytokines in the MBP-stimulated T cells, draining 
lymph nodes from EAE-induced mice were stimulated ex vivo with MBP for 
24  h,  and  cytokine  expression  was  determined  as  described.  Cells  were 
washed twice with PBS and resuspended in a permeabilization buffer (Cyto-
fix/Cytoperm kit; BD), and stained with fluorescently conjugated antibodies. 
Fluorescence intensity was measured by flow cytometry (FACScan; BD).
Detection of cytokines. Cytokine levels in culture supernatants were de-
termined by multiplexed bead array immunoassay using Luminex technol-
ogy (Bio-Plex; Bio-Rad Laboratories).
Real-time PCR. Total RNA was isolated from cell pellets using an RNeasy 
Mini Kit. Genomic DNA was removed using the RNase-free DNase Set for 
DNA digestion during RNA purification. First-strand cDNA synthesis was 
performed using a Sensiscript RT Kit with random hexamer primers (all kits 
were purchased from QIAGEN). Levels of mRNA of the gene of interest 
were quantified by real-time PCR (ABI 7900HT Sequence Detection Sys-
tem; Applied Biosystems) using SYBR Green Master Mix (Applied Biosys-
tems). Thermocycling included an initial incubation at 50°C for 2 min, then 
95°C for 10 min, followed by a two-step PCR program of 95°C for 15 s 
and 60°C for 60 s, for a total of 40 cycles. The total amount of mRNA was 
Our data demonstrate that TGF- plays an indirect role 
in the differentiation of Th17 cells. In the absence of Th1 and 
Th2 cells, IL-6 alone was sufficient to induce Th17 cell dif-
ferentiation. IL-6 is a pleiotropic cytokine that has been im-
plicated in many autoimmune and inflammatory conditions 
(Schett, 2008; Schett and David, 2008). In agreement with 
earlier reports, our data demonstrate that IL-6 plays a central 
role in the differentiation of pathogenic Th17 cells. In addi-
tion, IL-6 constricts suppressor functions of T reg cells, which 
facilitate the generation of adaptive immune responses (Pasare 
and Medzhitov, 2003). Thus, IL-6–deficient animals are de-
fective in mounting adaptive immune responses and are resis-
tant to several autoimmune diseases (Pollard et al., 2003). 
Neutralization of IL-6 or blockade of its receptor by antibod-
ies ameliorates inflammation in several autoimmune diseases. 
Treatment modalities that are based on IL-6 are currently in 
advanced clinical trials (Lin et al., 2006; Sebba, 2008). In 
contrast, TGF- is well known for its immunosuppressive 
functions (Wahl and Chen, 2003). It inhibits both innate and 
adaptive immune responses, including the differentiation of 
Th1 and Th2 cells. Deficiency of TGF- or impairment of 
TGF- signaling leads to the spontaneous differentiation   
of Th1 and Th2 cells (Gorelik and Flavell, 2000). Therefore, 
animals deficient in TGF- or TGF-RIIDN develop mul-
tiple organ autoimmunity (Kulkarni and Karlsson, 1997; Gorelik 
and Flavell, 2000). However, our study indicates that TGF- 
is incapable of inhibiting the differentiation program of   
Th17 cells. Thus, our study is consistent with the established 
immunosuppressive activities of TGF-, which inhibits Th1 
and Th2 immune responses but spares Th17 cells.
In summary, we have shown that TGF- promotes the 
differentiation of Th17 cells not by acting directly on the 
molecular orchestration of these cells but rather by inhibiting 
the development of Th1 and Th2 cells. Recently, it has been 
shown that TGF- is not essential for the differentiation of 
IL-17–producing human Th cells (Acosta-Rodriguez et al., 
2007). On the other hand, some investigators have found 
that TGF- plays a critical role in the differentiation of   
human Th17 cells from naive CD4+ T cell populations (Yang 
et al., 2008a). Nonetheless, the precise role of TGF- in the 
molecular orchestration of human Th17 cells was not estab-
lished. In our studies, we showed that mouse Th cells that 
lack the differentiation machinery for both Th1 and Th2 
cells (Stat-6/T-bet/ mice) do not require TGF- for 
Th17 cell differentiation. In fact, the absence of Th1 and 
Th2 cells in BALB/c mice allowed the differentiation of   
encephalitogenic Th17 cells and susceptibility to EAE. Al-
though TGF- was dispensable for Th17 cell differentiation 
in the absence of Th1 and Th2 cell responses, IL-6 was still 
required. Thus, inhibition of IL-6 or its molecular signaling 
interferes with the differentiation of pathogenic Th17 cells, a 
finding with potential clinical application for the treatment 
of autoimmune diseases. In fact, treatment modalities based 
on IL-6 inhibition are currently undergoing clinical trials in 
patients  with  several  types  of  autoimmune  inflammation 
(Choy et al., 2002).JEM VOL. 206, October 26, 2009 
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normalized across samples according to endogenous -actin mRNA. Primer 
sequences were as follows: -actin, (forward) 5-GTGGGCCGCCCTAG-
GCACCA-3  and  (reverse)  5-CTCTTTGATGTCACGCACGATT-3; 
GATA-3,  (forward)  5-TTATCAAGCCCAAGCGAAGG-3  and  (re-
verse)  5-CATTAGCGTTCCTCCTCCAGAG-3;  STAT-4,  (forward) 
5-CCTTCTCCCCATGTCTCCAAGT-3  and  (reverse)  5-CCGTTT-
GCACCGTCATTCA-3; Tbx21/T-bet, (forward) 5-ACAACCCCTTT-
GCCAAAGGA-3 and (reverse) 5-TCCCCCAAGCAGTTGACAGTT-3; 
IL-17, (forward) 5-CTCCAGAAGGCCCTCAGACTAC-3 and (reverse) 
5-AGCTTTCCCTCCGCATTGACACAG-3; RORt, (forward) 5-CC-
GCTGAGAGGGCTTCAC-3 and (reverse) 5-TGCAGGAGTAGGCCA-
CATTACA-3;  IL-21,  (forward)  5-CGCCTCCTGATTAGACTTCGTC-3 
and (reverse) 5-TGCCCCTTTACATCTTGTGGA-3; and STAT-6, (for-
ward) 5-GATCATGAACAACACGGTGCC-3 and (reverse) 5-CGCT-
CACAGCGCTTTATTTTCT-3.
Induction of EAE. Wild-type BALB/c mice, Stat-6/ mice, T-bet/ 
mice, or Stat-6/T-bet/ mice on a BALB/c background were immu-
nized s.c. at 6–8 wk of age with 200 µg of bovine MBP (4 mg/ml in saline; 
Sigma-Aldrich) and 200 µg of heat-killed Mycobacterium tuberculosis divided 
among three sites on their backs on days 0 and 7. On day 1 and again on day 
8, mice were injected i.p. with 100 ng pertussis toxin (List Biologicals). For 
cytokine neutralization experiments, mice were injected with 100 µg anti–
IL-17, anti–TGF-, or anti–IL-6 per mouse every 72 h. Disease scores were 
measured as follows: 1, tail paralysis; 2, hind limb weakness; 3, hind limb pa-
ralysis; 4, hind and forelimb paralysis; and 5, moribund.
Statistical  analyses. Differences in treatment groups were assessed by a 
paired two-tailed Student’s t test. The significance levels are indicated as fol-
lows: *, P < 0.03; **, P < 0.002; ***, P < 0.001; #, P < 0.003; ##, P < 0.01; 
and ###, P < 0.005.
Online supplemental material. Fig. S1 shows that Stat-6/T-bet/ 
mice are incapable of mounting Th1 and Th2 cell responses. Fig. S2 shows 
that neutralization of TGF- abrogates Th17 cell differentiation in naive 
CD4+ T cells from wild-type mice. Fig. S3 shows expression of FoxP3   
in Th17 cells. Fig. S4 shows that anti–IL-6 abrogates EAE in Stat-6/ 
T-bet/ mice. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20082286/DC1.
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